CABLIVI Patient Solutions

Going home from the hospital with a new medicine can be overwhelming. CABLIVI Patient Solutions is here to help you during this transition.

To sign up to receive a CABLIVI Welcome Kit and more, please fill out the CABLIVI Patient Solutions enrollment form or call 1-855-724-7222.* CABLIVI Patient Solutions is available Monday through Friday, 8:00 AM to 8:00 PM ET

Patient on couch
Caduceus

Specialty pharmacy services

Getting started

If your doctor prescribes CABLIVI through Biologics by McKesson
specialty pharmacy:

  • The specialty pharmacy will deliver CABLIVI to your home for a seamless adjustment after you leave the hospital
  • Nurses are available to provide ongoing support and answer questions about CABLIVI at the phone number above
  • Pharmacists are available 24 hours a day, 7 days a week

Refills

If your doctor decides you need a refill, you’ll receive a phone call from the specialty pharmacy to arrange your delivery of CABLIVI according to your doctor’s prescription.

Calculator

Financial assistance

  • Support is available to cover the cost of CABLIVI co-pay or co-insurance for qualified, commercially insured patients up to the program maximum
  • CABLIVI will be provided at no cost to eligible, underinsured, or uninsured patients
Syringe

Supplemental training

Clinical educators§ are available to provide:

  • Additional training on how to administer CABLIVI by yourself
  • Answers to questions about CABLIVI
  • Support in setting up a plan for administering therapy (eg, deciding a time to take CABLIVI each day)

*You must have been prescribed CABLIVI to receive a welcome kit and enroll in the program.

This offer is not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, Veterans Affairs, Department of Defense, TRICARE, or similar federal or state programs.

Approval is not guaranteed. Sanofi Genzyme reserves the right to modify or discontinue the programs at any time.

§CABLIVI clinical educators are paid to provide educational services. They don’t provide medical advice. You should always talk to your doctor about any healthcare needs.

CABLIVI Patient Solutions

Learn more about the support offered through CABLIVI Patient Solutions.

Download more information >

CABLIVI Patient Solutions Enrollment Form

Enroll in CABLIVI Patient Solutions for specialty pharmacy services, administration training, financial assistance, and more.

Download enrollment form >

IMPORTANT SAFETY INFORMATION

Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.

Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.

You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

The most common side effects include nosebleed, headache and bleeding gums.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

INDICATION

What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Back to the top